Cargando…

Defining the natural history of tumefactive demyelination: A retrospective cohort of 257 patients

OBJECTIVE: To describe demographic, clinical, and radiographic features of tumefactive demyelination (TD) and identify factors associated with severe attacks and poor outcomes. METHODS: Retrospective review of TD cases seen at Mayo Clinic, 1990–2021. RESULTS: Of 257 patients with TD, 183/257 (71%) f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fereidan‐Esfahani, Mahboubeh, Decker, Paul A, Weigand, Stephen D., Lopez Chiriboga, Alfonso S., Flanagan, Eoin P, Tillema, Jan‐Mendelt, Lucchinetti, Claudia F, Eckel‐Passow, Jeanette E., Tobin, W. Oliver
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502639/ https://www.ncbi.nlm.nih.gov/pubmed/37443413 http://dx.doi.org/10.1002/acn3.51844

Ejemplares similares

The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody
por: Höftberger, Romana, et al.
Publicado: (2020)

Recurrent tumefactive demyelination: An unusual presentation
por: Bhargava, Amita, et al.
Publicado: (2015)

A Case of Relapsing-Remitting Tumefactive Demyelination
por: Wadhwa, Ankur, et al.
Publicado: (2019)

Isolated Medullary Tumefactive Demyelination Masquerading as Tumor
por: Manoj,, et al.
Publicado: (2022)

Recurrent tumefactive demyelinating lesions in an elderly woman
por: Weil, Erika L., et al.
Publicado: (2022)

Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders
por: Sechi, Elia, et al.
Publicado: (2021)

Tumefactive demyelinating disease with isolated spinal cord involvement
por: Makary, Mina S, et al.
Publicado: (2014)

Silent Tumefactive Demyelinating Lesions and Radiologically Isolated Syndrome
por: Ekmekci, Ozgul, et al.
Publicado: (2018)

Tumefactive demyelination: Clinical outcomes, lesion evolution and treatments
por: Brod, Staley A, et al.
Publicado: (2019)

Case Report: Paraneoplastic Tumefactive Demyelination Associated With Seminoma
por: Shiraishi, Wataru, et al.
Publicado: (2022)

CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies
por: Zhao-Fleming, Hannah H., et al.
Publicado: (2021)

Tumefactive demyelination following herbal supplement use: Cause or coincidence?
por: Dubey, D, et al.
Publicado: (2016)

Progression of tumefactive demyelinating lesion in a child demonstrated with MRI
por: De Simone, Marta, et al.
Publicado: (2017)

Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab
por: Moreira Ferreira, Vanessa F., et al.
Publicado: (2019)

AZD-1222: Tumefactive demyelinating brain lesion : case report
Publicado: (2022)

Tumefactive Demyelination—A Rare Presentation of Anti-MOG Syndrome
por: Sivadasan, Sesh, et al.
Publicado: (2022)

Population-based study of “no evident disease activity” in MS
por: Parks, Natalie E., et al.
Publicado: (2018)

Pitfalls in the diagnosis of a tumefactive demyelinating lesion: A case report
por: Gavra, Maria, et al.
Publicado: (2011)

Neuroimaging features of tumefactive demyelinating lesions: A rare case report
por: Febyan, et al.
Publicado: (2020)

Immunopathology of Tumefactive Demyelinating Lesions-From Idiopathic to Drug-Related Cases
por: Vakrakou, Aigli G., et al.
Publicado: (2022)

Clinical spectrum and prognosis of pathologically confirmed atypical tumefactive demyelinating lesions
por: Zhang, Yajing, et al.
Publicado: (2023)

Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis
por: Lucchinetti, C. F., et al.
Publicado: (2008)

Tumefactive demyelination with a transient appearance of oligoclonal bands in MS under fingolimod
por: Okada, Kazumasa, et al.
Publicado: (2018)

Chinese Guidelines for the Diagnosis and Management of Tumefactive Demyelinating Lesions of Central Nervous System
Publicado: (2017)

Tumefactive Demyelination Associated with Bilateral Optic Neuritis in Neuromyelitis Optica Spectrum Disorders
por: Verma, Rajesh, et al.
Publicado: (2019)

Tumefactive demyelination after covid-19 successfully treated with betainterferon 1A
por: Araújo, Victor Oliveira, et al.
Publicado: (2022)

Long‐term clinical, imaging and cognitive outcomes association with MS immunopathology
por: Kalinowska‐Lyszczarz, Alicja, et al.
Publicado: (2023)

Cerebral Cortical Encephalitis in Myelin Oligodendrocyte Glycoprotein Antibody‐Associated Disease
por: Valencia‐Sanchez, Cristina, et al.
Publicado: (2022)

A rare presentation of atypical demyelination: tumefactive multiple sclerosis causing Gerstmann’s syndrome
por: Gnanapavan, Sharmilee, et al.
Publicado: (2014)

Corrigendum: Chinese Guidelines for the Diagnosis and Management of Tumefactive Demyelinating Lesions of Central Nervous System
Publicado: (2017)

Paraneoplastic recurrent tumefactive demyelination in a 62-year-old man with metastatic seminoma
por: Thebault, Simon, et al.
Publicado: (2018)

When tumefactive demyelination is truly a tumor: case report of a radiographic misdiagnosis
por: Taylor, Breanna, et al.
Publicado: (2021)

Neuromyelitis Optica Spectrum Disorder with Tumefactive Demyelination mimicking Multiple Sclerosis: A Rare Case
por: Roy, Ujjawal, et al.
Publicado: (2016)

Successful treatment of HIV-associated tumefactive demyelinating lesions with corticosteroids and cyclophosphamide: a case report
por: Lazzarin, Serena Marita, et al.
Publicado: (2020)

Progressive Tumefactive Demyelination as the Only Result of Extensive Diagnostic Work-Up: A Case Report
por: Štourač, Pavel, et al.
Publicado: (2021)

Tumefactive demyelinating CNS lesion in a 60-year-old woman with familial Mediterranean fever
por: Trostel, Constanze, et al.
Publicado: (2021)

Phenotyping variants of tumefactive demyelinating lesions according to clinical and radiological features—A case series
por: Boyle, Thérèse, et al.
Publicado: (2023)

Central nervous system tumefactive demyelinating lesions: Risk factors of relapse and follow-up observations
por: Li, Xinnan, et al.
Publicado: (2022)

Frequency of New or Enlarging Lesions on MRI Outside of Clinical Attacks in Patients With MOG-Antibody–Associated Disease
por: Syc-Mazurek, Stephanie B., et al.
Publicado: (2022)

Commentary: Tumefactive Demyelinating Lesions as a First Clinical Event: Clinical, Imaging, and Follow-up Observations
por: Koudriavtseva, Tatiana, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_37vu6hck668uirhof1b8bqok0e